期刊文献+

RP-HPLC法测定丁酸氯维地平原料药中有关物质 被引量:2

Determination of related substances in clevidipine butyrate bulks drug by RP-HPLC
原文传递
导出
摘要 目的建立测定丁酸氯维地平原料药中有关物质的RP-HPLC法。方法采用Welchrom C(18)色谱柱(250 mm×4.6 mm,5μm);流动相为甲醇–环己烷–水(70∶0.5∶30);体积流量为1 m L/min;柱温为30℃;检测波长为240 nm;进样体积为20μL。结果丁酸氯维地平及其14种杂质能够达到良好的分离;丁酸氯维地平及其杂质I、III、IV、V的质量浓度与峰面积的线性关系良好;丁酸氯维地平及其14种杂质的检测限(S/N≥3)在0.57~3.13 ng。结论该方法简便准确、重复性好,专属性强,精密度高,可用于丁酸氯维地平原料药中有关物质的测定。 Objective To establish an RP-HPLC method for determination of related substances in clevidipine butyrate bulks drug. Methods The separation was performed on a Welchrom C(18) column(250 mm × 4.6 mm, 5 μm) with methanol- cyclohexane- water(70∶0.5∶30) as mobile phase. The detection wavelength was set at 240 nm and the injection volume was 20 μL at the flow rate of 1.0 m L/min. The column temperature was 30 ℃. Results Clevidipine butyrate and 14 kinds of its impurities could be achieved good separation. There were good linear relationships of clevidipine butyrate and impurity I, III, IV, and V between concentration and peak, and the detection limits(S/N ≥ 3) were 0.57 — 3.13 ng. Conclusion This method is simple, accurate, reproducible, specific, and suitable for the determination of related substances in clevidipine butyrate bulks drug.
出处 《现代药物与临床》 CAS 2015年第12期1446-1450,共5页 Drugs & Clinic
关键词 丁酸氯维地平 有关物质 高效液相色谱 clevidipine butyrate related substances HPLC
  • 相关文献

参考文献4

二级参考文献37

  • 1ARONSON S, BOISVERT D, LAPP W. Isolated systolic hypertension is associated with adverse outcomes from coronary artery bypass grafting surgery[ J]. Anesth Analg, 2002,94(5 ) :1079 - 1084.
  • 2WEITZ HH. Perioperative cardiac complications [ J ]. Med Clin North Am, 2001,85(5) :1151 - 1169.
  • 3ERSTAD BL, BARLETTA JF. Treatment of hypertension in the perioperative patient [ J ]. Ann Pharmacother, 2000,34 ( 1 ) :66 - 79.
  • 4LESLIE JB. Incidence and aetiology of perioperative hypertension [ J ]. Acta Anaesthesiol Scand Suppl, 1993,37 ( 99 ) :5 - 9.
  • 5WEISS SJ, LONGNECKER DE. Perioperative hypertension: an overview[J]. Coron Artery Dis, 1993,4(5) :401 -406.
  • 6ESTAFANOUS FG, TARAZI RC. Systemic arterial hypertension associated with cardiac surgery [ J ]. Am J Cardlol, 1980,46 (4) :685 -694.
  • 7The Medicines Company. CLEVIPREX (clevidipine butyrate) emulsion[ EB/OL]. [ 2009 - 04 - 23 ]. http://dailymed, nlm. nih. gov/dailymed/drugInfo, cfm? id = 8664.
  • 8YI X, VIVIEN B, LYNCH C, et al. Clevidipine blockade of L- type Ca^2+ currents: steady-state and kinetic electrophysiological studies in guinea pig ventricular myocytes[J]. J Cardiovasc Pharmacol, 2000,36 ( 5 ) :592 - 600.
  • 9NORDLANDER M, SJOQUIST PO, ERICSSON H,et al. Pharmacodynamic, pharmacokinetic and clinical effects of clevidip- ine, an ultrashort-acting calcium antagonist for rapid blood pressure control [ J ]. Cardiovasc Drug Rev, 2004,22 ( 3 ) : 227 - 250.
  • 10KIELER-JENSEN N, JOLIN-MELLGARD A, NORDLANDER M, et al. Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery [ J ]. Acta Anaesthesiol Scand, 2000,44(2) :186 - 193.

共引文献13

同被引文献6

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部